Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma? - Abstract

Department of Radiotherapy, Guy's & St Thomas' NHS Foundation Trust, London, UK.

Academic Foundation Programme, Guy's and St Thomas' NHS Foundation Trust, London, UK; Department of Endocrinology, King's College Hospital, London, UK.



Androgen administration can cause prostate cancer progression and androgen deprivation therapy is a commonly used therapeutic modality in the treatment of prostate cancer. In trying to answer the posed clinical question, this article reviews the risks and benefits of testosterone replacement therapy in this setting and the published data from clinical series. Recommendations are made based on the available evidence.

Written by:
Landau D, Tsakok T, Aylwin S, Hughes S.   Are you the author?

Reference: Clin Endocrinol (Oxf). 2011 Sep 26. Epub ahead of print.
doi: 10.1111/j.1365-2265.2011.04233.x

PubMed Abstract
PMID: 21951017 Prostate Cancer Section